Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges (2022)
- Authors:
- USP affiliated authors: HALLAK, JAIME EDUARDO CECILIO - FMRP ; SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.1080/14740338.2022.2066650
- Subjects: ANTIDEPRESSIVOS; FÁRMACOS PSICOTRÓPICOS; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
- Keywords: Psilocybin; Adverse events; Depression; Rapid acting antidepressants; Psychedelics
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Expert Opinion on Drug Safety
- ISSN: 1474-0338
- Volume/Número/Paginação/Ano: v. 21, n. 6, p. 761-776, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ROSSI, Giordano Novak et al. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, v. 21, n. 6, p. 761-776, 2022Tradução . . Disponível em: https://doi.org/10.1080/14740338.2022.2066650. Acesso em: 11 fev. 2026. -
APA
Rossi, G. N., Hallak, J. E. C., Saiz, J. C. B., & Santos, R. G. dos. (2022). Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, 21( 6), 761-776. doi:10.1080/14740338.2022.2066650 -
NLM
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1080/14740338.2022.2066650 -
Vancouver
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1080/14740338.2022.2066650 - Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview
- Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: a transcultural study
- The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges
- Molecular pathways of the therapeutic effects of Ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant
- Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
- Psychedelic medicines in major depression: progress and future challenges
- Natural hallucinogens in mental health [Editorial]
Informações sobre o DOI: 10.1080/14740338.2022.2066650 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003114574.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
